Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis (BioSpace)

Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis

UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), announced the completion of enrollment in its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, an easy-to-use oral rinsing system designed to prevent and treat OM.

Alan Joslyn, Ph.D., president and CEO, stated, “The completion of enrollment represents the next key operational milestone in the continued progress toward completion of this important clinical trial evaluating the clinical efficacy and safety of our AG013 product candidate. Oral mucositis is a debilitating condition in head and neck cancer patients receiving chemoradiation, and it is our belief that AG013 will provide relief for patients at risk for the development of this condition and allow them to successfully complete their cancer treatment regimen. With the achievement of this significant corporate milestone, we remain on track to report results from this study in early 2020.”

Learn more about Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis.
Related news: Oragenics Making ‘Great Progress’ Enrolling Patients in Oral Mucositis Clinical Trial.

Oragenics Presents Interim Data on the AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019.
X